Systemic MV-Edm therapy by intravenous administration into mice bearing RPMI 8226 myeloma xenografts.

Intravenous administration of 7 doses of active MV-Edm (●) caused growth inhibition of RPMI 8226 myeloma xenografts, and 1 of 8 mice in the group showed complete regression. In the group treated with equivalent doses of UV-inactivated MV-Edm (○), all 8 mice were euthanized because of tumor burden 13 days after initial therapy. The difference in tumor growth in the 2 groups was significantly different (P = .002).